
Bicycle Therapeutics plc – NASDAQ:BCYC
Bicycle Therapeutics stock price today
Bicycle Therapeutics stock price monthly change
Bicycle Therapeutics stock price quarterly change
Bicycle Therapeutics stock price yearly change
Bicycle Therapeutics key metrics
Market Cap | 994.17M |
Enterprise value | 341.88M |
P/E | -5.47 |
EV/Sales | 23.63 |
EV/EBITDA | -3.18 |
Price/Sales | 44.02 |
Price/Book | 2.35 |
PEG ratio | 0.12 |
EPS | -4.45 |
Revenue | 41.59M |
EBITDA | -177.73M |
Income | -168.14M |
Revenue Q/Q | 298.66% |
Revenue Y/Y | 168.39% |
Profit margin | -779.35% |
Oper. margin | -802.72% |
Gross margin | 0% |
EBIT margin | -802.72% |
EBITDA margin | -427.25% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBicycle Therapeutics stock price history
Bicycle Therapeutics stock forecast
Bicycle Therapeutics financial statements
$39.25
Potential upside: 448.18%
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 11.39M | -42.60M | -373.81% |
---|---|---|---|
Sep 2023 | 5.35M | -49.89M | -932.32% |
Dec 2023 | 5.33M | -49.09M | -921.01% |
Mar 2024 | 19.51M | -26.54M | -136.01% |
Jun 2023 | 454170000 | 234.07M | 51.54% |
---|---|---|---|
Sep 2023 | 638683000 | 222.66M | 34.86% |
Dec 2023 | 595344000 | 224.41M | 37.69% |
Mar 2024 | 547143000 | 191.09M | 34.93% |
Jun 2023 | 34.09M | -277K | 12.29M |
---|---|---|---|
Sep 2023 | -1.02M | -502K | 234.63M |
Dec 2023 | -47.28M | -51K | 386K |
Mar 2024 | -70.82M | -11.99K | 1.86M |
Bicycle Therapeutics alternative data
Aug 2023 | 236 |
---|---|
Sep 2023 | 236 |
Oct 2023 | 236 |
Nov 2023 | 236 |
Dec 2023 | 236 |
Jan 2024 | 236 |
Feb 2024 | 236 |
Mar 2024 | 284 |
Apr 2024 | 284 |
May 2024 | 284 |
Jun 2024 | 284 |
Jul 2024 | 284 |
Bicycle Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 19876 |
Apr 2024 | 0 | 7222 |
Jul 2024 | 0 | 7268 |
Oct 2024 | 0 | 6528 |
Nov 2024 | 0 | 4944 |
Dec 2024 | 1485397 | 0 |
Insider | Compensation |
---|---|
Dr. Kevin Lee M.B.A., Ph.D. (1969) Chief Executive Officer & Executive Director | $1,160,000 |
Dr. Michael Skynner Ph.D., B.sc. Ph.d. (1970) Chief Operating Officer | $769,010 |
Mr. Lee H. Kalowski (1981) Pres & Chief Financial Officer | $756,130 |
Dr. Nigel Crockett Ph.D. (1965) Chief Bus. Officer | $568,120 |
Dr. Dominic Smethurst M.A., M.D. (1974) Chief Medical Officer | $431,700 |
Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE (1951) Co-Founder, Non-Executive Director & Member of Scientific Advisory Board | $40,000 |
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data
Bicycle Therapeutics: Decent Upside Opportunity, Mid-Stage Data Readouts Due
Bicycle Therapeutics: Not Much Differentiation Between Bicycles And mAbs Yet
Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Bicycle Therapeutics: An Oncology Play With Big Potential
Bicycle Therapeutics: Platform Technology Has Potential; Move To Combination Therapy With Opdivo Is Next
Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
-
What's the price of Bicycle Therapeutics stock today?
One share of Bicycle Therapeutics stock can currently be purchased for approximately $7.16.
-
When is Bicycle Therapeutics's next earnings date?
Unfortunately, Bicycle Therapeutics's (BCYC) next earnings date is currently unknown.
-
Does Bicycle Therapeutics pay dividends?
No, Bicycle Therapeutics does not pay dividends.
-
How much money does Bicycle Therapeutics make?
Bicycle Therapeutics has a market capitalization of 994.17M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 86.52% to 26.98M US dollars.
-
What is Bicycle Therapeutics's stock symbol?
Bicycle Therapeutics plc is traded on the NASDAQ under the ticker symbol "BCYC".
-
What is Bicycle Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Bicycle Therapeutics?
Shares of Bicycle Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Bicycle Therapeutics's key executives?
Bicycle Therapeutics's management team includes the following people:
- Dr. Kevin Lee M.B.A., Ph.D. Chief Executive Officer & Executive Director(age: 56, pay: $1,160,000)
- Dr. Michael Skynner Ph.D., B.sc. Ph.d. Chief Operating Officer(age: 55, pay: $769,010)
- Mr. Lee H. Kalowski Pres & Chief Financial Officer(age: 44, pay: $756,130)
- Dr. Nigel Crockett Ph.D. Chief Bus. Officer(age: 60, pay: $568,120)
- Dr. Dominic Smethurst M.A., M.D. Chief Medical Officer(age: 51, pay: $431,700)
- Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE Co-Founder, Non-Executive Director & Member of Scientific Advisory Board(age: 74, pay: $40,000)
-
Is Bicycle Therapeutics founder-led company?
Yes, Bicycle Therapeutics is a company led by its founder Sir Gregory Paul Winter CBE, FMedsci, FRS, HonFRCP, HonFTSE.
-
How many employees does Bicycle Therapeutics have?
As Jul 2024, Bicycle Therapeutics employs 284 workers.
-
When Bicycle Therapeutics went public?
Bicycle Therapeutics plc is publicly traded company for more then 6 years since IPO on 23 May 2019.
-
What is Bicycle Therapeutics's official website?
The official website for Bicycle Therapeutics is bicycletherapeutics.com.
-
How can i contact Bicycle Therapeutics?
Bicycle Therapeutics can be reached via phone at +44 1223 261503.
-
What is Bicycle Therapeutics stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Bicycle Therapeutics in the last 12 months, the avarage price target is $39.25. The average price target represents a 448.18% change from the last price of $7.16.
Bicycle Therapeutics company profile:

Bicycle Therapeutics plc
bicycletherapeutics.comNASDAQ
284
Biotechnology
Healthcare
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Cambridge, CB22 3AT
CIK: 0001761612
ISIN: US0887861088
CUSIP: 088786108